McKinsey January 9, 2026
From new consumer channels to AI-powered agents and robots, life sciences leaders have expanding options to create value in the year ahead.
One year ago, the McKinsey Life Sciences Practice released our RewiR&D collection, which explored how companies could “make more medicines that matter” through meaningful improvements in R&D productivity. That collection highlighted a long-standing truth: Progress across the industry—from medicines to devices, diagnostics, and digital tools—depends not only on efficiently translating science into solutions but also on ensuring those solutions endure and create sustained value.
As we enter 2026, the value creation imperative has taken on new urgency, and with it, a renewed focus on growth and enterprise performance.
Growth as the defining measure of performance
The operating landscape...
Today's Sponsors
Today's Sponsor